Market Place
Sourcing Support
Recursion And Exscientia Combine To Advance AI Drug Discovery
20 Nov 2024 //
GLOBENEWSWIRE
Exscientia Achieves Milestones In Sanofi Collaboration Programs
16 Oct 2024 //
BUSINESSWIRE
Exscientia`s Data for AI-designed LSD1 Inhibitors at ENA 2024
09 Oct 2024 //
BUSINESSWIRE
Exscientia To Present At Morgan Stanley Healthcare Conference
28 Aug 2024 //
BUSINESSWIRE
Exscientia Business Update for Second Quarter and First Half 2024
15 Aug 2024 //
BUSINESSWIRE
AI biotechs Exscientia and Recursion agree $688m merger
10 Aug 2024 //
PHARMAPHORUM
Exscientia Gains Full Control Of CDK7 Drug, Plans Breast Cancer Trial
19 Jul 2024 //
FIERCE BIOTECH
Exscientia Acquires Full Rights To CDK7 Inhibitor Pre-Phase 1 Readout
18 Jul 2024 //
BUSINESSWIRE
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
10 Jul 2024 //
BUSINESSWIRE
Exscientia Appoints Leaders To Boost Integrated Tech, Oncology Expertise
06 Jun 2024 //
BUSINESSWIRE
Exscientia to Present at Upcoming Investor Conferences in June
30 May 2024 //
BUSINESSWIRE
Regeneron faces new biosimilar threats; an AI biotech lays off staff
22 May 2024 //
BIOPHARMADIVE
Exscientia Business Update for First Quarter 2024
21 May 2024 //
BUSINESSWIRE
Exscientia cuts a quarter of staff while preserving AI pipeline
21 May 2024 //
FIERCE BIOTECH
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
14 May 2024 //
BUSINESSWIRE
Exscientia Business and Financial Update for the Full Year 2023
21 Mar 2024 //
BUSINESSWIRE
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
14 Mar 2024 //
BUSINESSWIRE
Exscientia to Present at Upcoming Investor Conferences in March
28 Feb 2024 //
BUSINESSWIRE
Exscientia fires CEO Andrew Hopkins effective immediately
14 Feb 2024 //
FIERCE BIOTECH
Exscientia Initiates Study to Evaluate Functional Precision Medicine Platform
07 Feb 2024 //
BUSINESSWIRE
Exscientia Announces Expansion of its Current Collaboration with Sanofi
21 Dec 2023 //
BUSINESSWIRE
Exscientia Receives Philanthropy Grant for Therapeutic Approach for Influenza
05 Dec 2023 //
BUSINESSWIRE
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
BUSINESSWIRE
Exscientia Business Update for Third Quarter 2023
09 Nov 2023 //
BUSINESSWIRE
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
02 Nov 2023 //
BUSINESSWIRE
Exscientia to Present New Preclinical Data for AI-designed LSD1
16 Oct 2023 //
BUSINESSWIRE
Exscientia Details Pipeline Prioritisation Strategy
03 Oct 2023 //
BUSINESSWIRE
Exscientia ends cancer study as it focuses on trials of AI-driven candidates
03 Oct 2023 //
ENDPTS
Merck KGaA taps BenevolentAI, Exscientia for AI drug discovery
21 Sep 2023 //
FIERCE BIOTECH
Exscientia to Present at Upcoming Investor Conferences in September
31 Aug 2023 //
BUSINESSWIRE
Exscientia Business Update for Second Quarter and First Half of 2023
10 Aug 2023 //
BUSINESSWIRE
Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
03 Aug 2023 //
BUSINESSWIRE
Exscientia Initiates Prospective Observational Study in Ovarian Cancer
18 Jul 2023 //
BUSINESSWIRE
Exscientia Announces Expansion of its Technology Leadership Team
29 Jun 2023 //
BUSINESSWIRE
Exscientia to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06 Jun 2023 //
BUSINESSWIRE
Exscientia Business Update for First Quarter 2023
24 May 2023 //
BUSINESSWIRE
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
22 May 2023 //
BUSINESSWIRE
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
17 May 2023 //
BUSINESSWIRE
Exscientia Announces Sixth Molecule Created Through Generative AI Platform
15 May 2023 //
BUSINESSWIRE
Verve names second PCSK9 candidate; Exscientia picks molecule for clinic
15 May 2023 //
ENDPTS
Exscientia Appoints Harvard Professor Franziska Michor to Board of Directors
03 May 2023 //
PRESS RELEASE
Exscientia Business and Financial Update for the Full Year 2022
23 Mar 2023 //
BUSINESSWIRE
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
16 Mar 2023 //
BUSINESSWIRE
Exscientia to Present Data Precision Medicine Platform at AACR
15 Mar 2023 //
BUSINESSWIRE
Exscientia Announces Expansion of its Precision Oncology Pipeline
14 Mar 2023 //
BUSINESSWIRE
Exscientia Announces Collaboration with Charité for Precision Medicine Platform
07 Mar 2023 //
BUSINESSWIRE
Exscientia to Present at Upcoming Investor Conferences in March
22 Feb 2023 //
BUSINESSWIRE
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
02 Feb 2023 //
BUSINESSWIRE
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546
06 Dec 2022 //
BUSINESSWIRE
Exscientia receives approval to begin advanced solid tumour therapy trial
29 Nov 2022 //
CLINICALTRIALSARENA
Exscientia Receives First CTA Approval to Initiate IGNITE-AI
28 Nov 2022 //
BUSINESSWIRE
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI
14 Nov 2022 //
PRESS RELEASE
Exscientia tapped by MD Anderson for AI drug discovery efforts
14 Nov 2022 //
FIERCEBIOTECH
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
08 Nov 2022 //
BUSINESSWIRE
Exscientia Expands Biologics Design Capability with Automated Laboratory
03 Nov 2022 //
BUSINESSWIRE
Exscientia expands AI drug design reach to complex antibodies
03 Nov 2022 //
FIERCEBIOTECH
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
28 Oct 2022 //
BUSINESSWIRE
Exscientia Presents Patient Stratification & Biomarker Data for GTAEXS-617
26 Oct 2022 //
BUSINESSWIRE
Exscientia Welcomes Caroline Rowland as Chief People Officer
08 Sep 2022 //
BUSINESSWIRE
Exscientia to Present at Upcoming Investor Conferences in September
07 Sep 2022 //
BUSINESSWIRE
